UNIVERSITY OF MOUNT UNION HEALTH RECORD

Name				Social	Security #	
			MIDDLE		•	
Address			CITY		STATE Z.	IP CODE
Date of Birth M F Country of		F Country of Bir	th	_ Student Cell Phone		
Person to Notify in an Eme	ergency	У			(D. 1. c)	1 •)
Address of Above					(Relations	ship)
Home Phone			Work Phone		Cell Phone	
			FAMILY HEAL	TH HISTORY		
CHECK EACH ITEM	YES	NO	RELATIONSHIP	CHECK EACH ITEM	YES NO	RELATIONSHIP
TUBERCULOSIS				ASTHMA, HAY FEVER, H	IIVES 🔲 🗋	
DIABETES				EPILEPSY OR CONVULSI	ions 🔲 🗋	
HIGH BLOOD PRESSURE/STROKE				NERVOUS OR MENTAL I	DISORDER 🔲 🗋	
HEART TROUBLE				BLEEDING/CLOTTING D	DISORDER 🔲 🗋	
CANCER				OTHER		
ASTHMA RHEUMATIC FEVER HEART PROBLEMS SKIN PROBLEMS ALLERGIES/HAY FEVER ARTHRITIS THYROID PROBLEMS STOMACH OR BOWEL PROBLEMS If yes, or any other medical			BLOOD DISORDER DIABETES HEPATITIS/ JAUNDICE ORTHOPEDIC PROBLEM SEIZURES/CONVULSION HIGH BLOOD PRESSURE HIV TUBERCULOSIS		MIGRAINE HEADACHE TOBACCO USE DEPRESSION/ANXIETY MUMPS SURGERY ALCOHOL/DRUG ABUSE KIDNEY/BLADDER ADHD/ADD	Yes No
Check Each Item Do you take medication?			Yes No If yes, list:	Authorization is he student, for the Ph	EMENT OF AUTHOR ereby granted, for the health a ysician or Physician Assistant essary, and to refer this studen	nd welfare of the t to admit him/her to
Are you allergic to any medicati	ons or la	atex?		 physician or surged 	on when indicated. Permissio d-ication, treatment, vaccines	n is given to
Are you allergic to any foods?			Signature of Stude	ent	Date	
				- Signature of Parer	nt/Guardian (if student is under 1	18 years of age) Date

UNIVERSITY OF MOUNT UNION HEALTH RECORD

Student			
Social Security Number	Date	of Birth	
Please indicate what insurance coverage	e you have:		
Student insurance – Available	e through the University of Mount Unio	n	
Private insurance through a private insurance insuran	parent/spouse – Please complete the info	rmation belo	W
Primary Insurance: Please include cop	y of insurance card- front and back.		
Name of Policy holder		DOB	
Address	City	State	Zip
Phone	Relationship of insured to student		
Employer			
Address	City	State	Zip
Insurance Company Phone			
Member ID	Group No		
Secondary Insurance: Please include of			
Name of Policy holder		DOB	
Address	City	State	Zip
Phone	Relationship of insured to student		
Employer	City	State	Zip
Insurance Company			
Address	City	State	Zip
Insurance Company Phone			
Member ID	Group No		

2

Part I: <u>Tuberculosis (TB) Screening Questionnaire</u> (to be completed by incoming students)

Please answer the following questions:

Have you ever had close cor	disease?	□ Yes	🛛 No			
Were you born in one of the countries or territories listed below that have a high incidence of active TB \Box Yes \Box No disease? (If yes, please CIRCLE the country, below)						
Argentina	Comoros Congo Côte d'Ivoire Democratic People's Republic of Korea Democratic Republic of the Congo Djibouti Dominican Republic Ecuador El Salvador Equatorial Guinea Eritrea Ethiopia Fiji Gabon Gambia Georgia Ghana Greenland Guatemala Guinea Guinea-Bissau Guyana Haiti Honduras India Indonesia	Iraq Kazakhstan Kenya Kiribati Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lesotho Liberia Libya Lithuania Madagascar Malawi Malaysia Maldives Mali Marshall Islands Mauritania Mauritania Mauritius Mexico Micronesia (Federated States of) Mongolia Montenegro Morocco Mozambique Myanmar	Namibia Nauru Nepal New Caledonia Nicaragua Niger Nigeria Northern Mariana Islands Pakistan Palau Panama Papua New Guinea Paraguay Peru Philippines Portugal Qatar Republic of Korea Republic of Korea Republic of Moldova Romania Russian Federation Rwanda Sao Tome and Principe Senegal Serbia Sierra Leone Singapore Solomon Islands	Somalia South Africa South Sudan Sri Lanka Sudan Suriname Swaziland Syrian Arab R Tajikistan Tanzania (Uni Republic of) Thailand Timor-Leste Togo Tunisia Turkmenistan Turkmenistan Tuvalu Uganda Ukraine Uruguay Uzbekistan Vanuatu Venezuela (Bo Republic of) Viet Nam Yemen Zambia Zimbabwe	ted	

Source: World Health Organization Global Health Observatory, Tuberculosis Incidence 2015. Countries with incidence rates of ≥ 20 cases per 100,000 population. For future updates, refer to <u>http://www.who.int/tb/country/en/</u>.

Have you had frequent or prolonged visits* to one or more of the countries or territories listed above with a high prevalence of TB disease? (If yes, CHECK the countries or territories, above)	□ Yes	No
Have you been a resident and/or employee of high-risk congregate settings (e.g., correctional facilities, long-term care facilities, and homeless shelters)?	□ Yes	🛛 No
Have you been a volunteer or health care worker who served clients who are at increased risk for active TB disease?	□ Yes	No
Have you ever been a member of any of the following groups that may have an increased incidence of latent <i>M. tuberculosis</i> infection or active TB disease: medically underserved, low-income, or abusing drugs or alcohol?	□ Yes	No

If the answer is YES to any of the above questions, the University of Mount Union requires that you receive TB testing as soon as possible.

If the answer to all of the above questions is NO, no further testing or further action is required.

* The significance of the travel exposure should be discussed with a health care provider and evaluated.

Part II. Clinical Assessment by Health Care Provider

Clinicians should review and verify the information in Part I. Persons answering YES to any of the questions in Part I are candidates for either Mantoux tuberculin skin test (TST) or Interferon Gamma Release Assay (IGRA) unless a previous positive test has been documented.

History of a positive TB skin test or IGRA blood test? (If yes, document below)	Yes	_ No
History of BCG vaccination? (If yes, consider IGRA if possible.)	Yes	_ No

1. TB Symptom Check

Does the student have signs or symptoms of active pulmonary tuberculosis disease?	Yes	No	
-----------------------------------------------------------------------------------	-----	----	--

If No, proceed to 2 or 3

If yes, check below:

- Cough (especially if lasting for 3 weeks or longer) with or without sputum production
- Coughing up blood (hemoptysis)
- □ Chest pain
- □ Loss of appetite
- □ Unexplained weight loss
- □ Night sweats
- □ Fever

Proceed with additional evaluation to exclude active tuberculosis disease including tuberculin skin testing, chest x-ray, and sputum evaluation as indicated.

2. Tuberculin Skin Test (TST)

(TST result should be recorded as actual millimeters (mm) of induration, transverse diameter; if no induration, write "0". The TST interpretation should be based on mm of induration as well as risk factors.)**

Date Given: _	//	Date Read://
	M D Y	M D Y
Result:	mm of induration	**Interpretation: positive negative
Date Given: _	///Y	Date Read:///
Result:	mm of induration	**Interpretation: positive negative

****Interpretation guidelines**

>5 mm is positive:

- Recent close contacts of an individual with infectious TB
- persons with fibrotic changes on a prior chest x-ray, consistent with past TB disease
- organ transplant recipients and other immunosuppressed persons (including receiving equivalent of >15 mg/d of prednisone for >1 month.)
- HIV-infected persons

>10 mm is positive:

- recent arrivals to the U.S. (<5 years) from high prevalence areas or who resided in one for a significant* amount of time
- injection drug users
- mycobacteriology laboratory personnel
- residents, employees, or volunteers in high-risk congregate settings
- persons with medical conditions that increase the risk of progression to TB disease including silicosis, diabetes mellitus, chronic renal failure, certain types of cancer (leukemias and lymphomas, cancers of the head, neck, or lung), gastrectomy or jejunoileal bypass and weight loss of at least 10% below ideal body weight.

>15 mm is positive:

 persons with no known risk factors for TB who, except for certain testing programs required by law or regulation, would otherwise not be tested. * The significance of the travel exposure should be discussed with a health care provider and evaluated.

3. Interferon Gamma Release Assay (IGRA)

Date Obtained: $////////////////////////////////////$	(specify method)	QFT-GIT	T-Spot	other
Result: negative positive	indeterminate	_ borderli	ne (T-S	pot only)
Date Obtained:///////	(specify method)	QFT-GIT	T-Spot	other
Result: negative positive	indeterminate	_ borderlin	ne (T-S	pot only)

4. Chest x-ray: (Required if TST or IGRA is positive)

Date of chest x-ray: ___/__/ Result: normal____ abnormal____

Part III. Management of Positive TST or IGRA

All students with a positive TST or IGRA with no signs of active disease on chest x-ray should receive a recommendation to be treated for latent TB with appropriate medication. However, students in the following groups are at increased risk of progression from LTBI to TB disease and should be prioritized to begin treatment as soon as possible.

- □ Infected with HIV
- **C** Recently infected with *M. tuberculosis* (within the past 2 years)
- □ History of untreated or inadequately treated TB disease, including persons with fibrotic changes on chest radiograph consistent with prior TB disease
- Receiving immunosuppressive therapy such as tumor necrosis factor-alpha (TNF) antagonists, systemic corticosteroids equivalent to/greater than 15 mg of prednisone per day, or immunosuppressive drug therapy following organ transplantation
- Diagnosed with silicosis, diabetes mellitus, chronic renal failure, leukemia, or cancer of the head, neck, or lung
- □ Have had a gastrectomy or jejunoileal bypass
- □ Weigh less than 90% of their ideal body weight
- □ Cigarette smokers and persons who abuse drugs and/or alcohol

_____Student agrees to receive treatment

_____Student declines treatment at this time

Health Care Professional Signature

Date

MANDATORY IMMUNIZATIONS REQUIRED BY THE UNIVERSITY OF MOUNT UNION

A. M.M.R. (Measles, Mumps, Rubella) (Two doses required at least 28 days apart.)

	Dose #1/ Dose #2/ M Y M Y
B.	Tetanus-Diphtheria-Pertussis
	1. Primary series completed? Yes No
	Date of last dose in series
	2. Date of most recent booster dose – must be within 10 years
	Type of booster: Td Tdap (Preferred)
	Tdap booster recommended for ages 11-64 unless contraindicated
HI	GHLY RECOMMENDED IMMUNIZATIONS - (Refer to www.acha.org for recommendations)
C.	Polio (Primary series, doses at least 28 days apart. Any of the three primary series are acceptable. See ACIP website for details).
	1. OPV alone (oral Sabin three doses):
	2. IPV/OPV sequential: IPV #1/ IPV #2/ OPV #3/ OPV #4/
	3. IPV alone (injected Salk four doses): #1/ #2/ #3/ #4/
D.	Pneumococcal Polysaccharide Vaccine (One dose for members of high-risk groups.) Date/ M Y
E.	Influenza (Annually) Date/ M Y
F.	Varicella (Birth in the U.S. before 1980, a history of chicken pox, a positive Varicella antibody, or two doses of vaccine meets the requirement.)
	1. ImmunizationDose #1/_ MDose #2/_ M(Given at least 12 weeks after first dose ages 1-12 years and at least 4 weeks after first dose if age 13 years or older)
	2. History of Disease Yes No OR Birth in U.S. before 1980 Yes No
	3. Varicella antibody/ Result: Reactive Non-reactive

6

Name

H.

I.

J.

K.

G. Hepatitis B*

(Three doses of vaccine or two doses of adult vaccine in adolescents 11-15 years of age, or a positive hepatitis B surface antibody meets the requirement.)

1. Immunization D	ose #1/	Dose #2/	Dose #3/
	<u>M</u> Y	<u>M</u> Y	<u>M</u> Y
	dult formulation hild formulation	Adult formulation Child formulation	Adult formulation Child formulation
•	tibody Date/		Non-reactive
 Hepatitis A Immunization Dose #1/ M 	Dose #2 Y	/ M Y	
Hepatitis A & B Combine	d Vaccine		
		Dose #3/_	Y
Meningococcal Vaccine (At least one dose at age 16 or great Quadrivalent conjugate		er simultaneously with Tdap	if possible):
Dose #1/	-		•
		native if conjugate not availal	ble) Date/ M Y
Meningococcal B			171 1
Dose #1/ M Y	Dose #2/	-	
. Human Papillomavirus Va	ccine	nting series after 15th birthday or HP	V9)
(indicate which preparation	on) (Quadrivalent (HPV4)	OR Bivalent (HPV2)
Dose #1/ Y	Dose #2 N	/ D	ose #3/ Y

Information Needed for the Office of Residence Life

*In order to comply with an Ohio law, which went into effect July 1, 2005, any student planning on living on campus must be informed of the risk associated with and the benefits of vaccination for meningitis and hepatitis B. In accordance with this law, we are providing you with the link to the Ohio Department of Health website (www.odh.ohio.gov) for further information.

Please not that this law does not require vaccination, nor does it require the institution to provide or pay for these vaccines. It requires only disclosure of whether or not you have been vaccinated.

Your signature below will suffice as a release for the Health Center to be able to share the information regarding only those immunizations with the Office of Residence Life, should the need arise.

(signature and date)

Immunization forms adapted from the American College Health Association

PLEASE RETURN TO UNIVERSITY OF MOUNT UNION, HEALTH CENTER, 1972 CLARK AVENUE, ALLIANCE, OH 44601

7